After two major indexes reached all-time highs, pharmaceutical stocks for companies in drug trials were caught up in the energy and rocketed forward. The largest gainers were$Spyre Therapeutics (SYRE.US)$, up 26% Monday morning, and$Gyre Therapeutics (GYRE.US)$+10%.
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel.$Ginkgo Bioworks (DNA.US)$also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not all roses for the biotech sector. Gilead Sciences fell 9% after a phase three lung cancer treatment trial failed to meet goals. ZLAB Zai Lab fell 7%
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
103398487 : thanks..is syre a good buy today at current price of 20.640 ?